Drug Database
Back to search

Poland· PL-100288446

Sovaldi

A sofosbuvir product containing sofosbuvirum, registered in Poland by Gilead Sciences Ireland UC. The same ATC class is registered in 13 of our 19 countries.

ATC J05AP08

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedSovaldiATCJ05AP08REGISTER NO.PL-100288446PACKS LISTED1CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about sofosbuvirumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Sofosbuvir is registered in 13 of 19 countries.

Countries holding a registration under ATC J05AP08 (sofosbuvir), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 8 of them publish a price we can compare per daily dose
Search sofosbuvir products by name

Sofosbuvir · ATC J05AP08

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of sofosbuvir costs, country by country.

Normalised to the WHO defined daily dose (0.4 g), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Sofosbuvir · price per daily dose (0.4 g)

USD · FX 28 Sept 2026

  • FR France$0.30
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Sofosbuvirum
Manufacturer
Gilead Sciences Ireland UC
Country
Poland (PL)
ATC code
J05AP08
ATC class
Sofosbuvir
Defined daily dose
0.4 g, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 1

  • gtin
    05391507140975

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

10 interactions on record for sofosbuvir.

Graded by severity as the source publishes them — 4 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check sofosbuvir against other medicinesHow interaction checks work

Sofosbuvir · interactions on record

10 records

  • 4 severe
  • 5 moderate
  • 1 minor

Most severe, free to view

  • LorlatinibL01ED05severe
  • LorlatinibL01XE44severe
  • EnzalutamideL02BB04severe
  • ApalutamideL02BB05severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Sofosbuvir in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All sofosbuvir products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Sovaldi
  • Liechtenstein · Sovaldi
  • Norway · Sovaldi

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/c06cba48-2293-4f46-a45f-8b6a146ac08a
GET /v1/drugs/c06cba48-2293-4f46-a45f-8b6a146ac08a?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki powlekane",
  "source": "urpl",
  "strength": "400 mg",
  "packaging": "Rpz ¦ EU/1/13/894/002 ¦ 90458\n1 butelka 84 tabl.\n05391507140975 ¦ Rpz ¦ EU/1/13/894/001 ¦ 90575\n1 butelka 28 tabl.",
  "substance": "Sofosbuvirum 400 mg",
  "common_name": "Sofosbuvirum",
  "pl_product_id": "100288446",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}
API referenceMCP serverPlans

See everything about sofosbuvir.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console